Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ocriplasmin - Oxurion

Next Previous
X
Search
Drug Profile

Ocriplasmin - Oxurion

Alternative Names: A-01016; Jejetrea®; Jetrea; Microplasmin; Recombinant human microplasmin; Recombinant microplasmin; THR-409

Latest Information Update: 22 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Leuven
  • Developer Alcon; Oxurion; ThromboGenics; University of Leuven
  • Class Anti-ischaemics; Eye disorder therapies; Peptide fragments; Serine endopeptidases
  • Mechanism of Action Antiplasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinal disorders; Peripheral arterial occlusive disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes - Thrombosis

Highest Development Phases

  • Marketed Retinal disorders
  • Phase II Diabetic retinopathy
  • Suspended Deep vein thrombosis; Peripheral arterial occlusive disorders; Stroke
  • No development reported Retinal vein occlusion
  • Discontinued Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

  • 05 Jan 2021 ThromboGenics and Wagner Macula and Retina Center terminates the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)
  • 12 Mar 2020 Ocriplasmin licensed to Inceptua Medicine worldwide for commercialisation
  • 04 Oct 2019 ThromboGenics and Wagner Macula and Retina Center initiates enrolment in the phase II TOTEM trial for Retinal disorders (Vitreomacular traction) in USA (Intravitreous) (NCT04300881)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top